Sirius Medical is delighted to contribute to the iBRA-NET Localization study
Sirius Medical, a leader in tumor navigation technology, announced today that multiple key hospitals in Europe coordinated by Mr. Edward St John at the Portsmouth Hospitals University NHS Trust will evaluate the safety and effectiveness of Sirius Pintuition® for the iBRA-NET Localization study. iBRA-NET is a multi-disciplinary group of breast and plastic surgeons, allied professionals, and patients from across the UK.
The Localization study is focused on non-palpable breast tumors and axillary lesions. Sirius Medical invites hospitals in Europe to join this study, whether they are new or established. The goal is to compare the outcomes to both the wire and other breast localization devices. The iBRA-NET group stimulates innovations and helps with evaluation of new surgical techniques, product, and implants within the field of oncoplastic breast surgery. “There is no innovation without evaluation”.
Do you want to join the iBRA-NET study
Sirius Medical will have a more in-depth symposium session about iBRA-NET study during the Association of Breast Surgery conference in Liverpool on the 16th and 17th May. This symposium will include talks about the surgeons’ experience with Sirius Pintuition, the iBRANET registry and a hands-on workshop to experience Sirius Pintuition powered by GPSDetect™.
Bram Schermers, CEO Sirius Medical: “We at Sirius Medical constantly seek collaboration with Institutions to expand medical knowledge in tumor navigation technologies. We welcome and support independent research. The iBRA-NET Localization study is a unique opportunity to contribute to further show the value of Sirius Pintuition as a tumor navigation technology and meet the demand of both users and patients to move away from wires”
Mr. Edward St John, consultant oncoplastic breast surgeon in Portsmouth, UK and Chief Investigator of the iBRA-NET Localization audit: “I am excited to launch the Real World Evidence Registry aimed at evaluating the safety and efficacy of current techniques of breast localization. The iBRA-NET research group has already published evidence by comparing MagSeed with wires. We aim to do the same with other localization systems including Sirius Pintuition both in the primary breast lesions and the axilla. Looking forward to collaborating with supporting Institutions around Europe!”
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors.
Sirius Medical offers Pintuition®, powered by GPSDetect™, a state-of-the-art navigation technology for the treatment of non-palpable breast cancer and other soft tissue tumor types is CE marked and FDA 510(k) cleared. The system is an intuitive, wire-free surgical navigation system with a unique multi-sensor probe that provides real-time directional guidance using audio and visual feedback for unmatched precision to locate tumors easily and accurately. Pintuiton is simple, precise, and affordable.
Sirius Medical has experienced business development and surgical support teams in Western Europe and the US.
The iBRA-NET is a multi-disciplinary group of breast and plastic surgeons, allied professionals, and patients from across the UK. They highlight innovations and develop studies for the evaluation of new surgical techniques, products, and implants within the field of oncoplastic breast surgery. iBRA-NET is supported by The Association of Breast Surgery (ABS), The British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) and The Royal College of Surgeons of England (RCSEng).